GTS Securities’s Seres Therapeutics MCRB Stock Holding History

GTS Securities’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-675	Closed	-$32.1K	–	4262
2023 Q3	$32.1K	Buy	+675	New	+$51.5K	﹤0.01%	3762

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GTS Securities's MCRB Position: Q4 2023 in Review

GTS Securities sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 675 shares — an estimated $32.1K sold.

GTS Securities first reported a position in MCRB in Q3 2023 and held it in 1 quarter. The position peaked at $32.1K in Q3 2023. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

GTS Securities reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
GTS Securities sold 675 Seres Therapeutics shares in Q4 2023, an estimated $32.1K.
GTS Securities first reported a position in Seres Therapeutics in Q3 2023 and held it in 1 quarter.
GTS Securities's Seres Therapeutics position peaked at $32.1K in Q3 2023.
102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on GTS Securities's 13F filing for Q4 2023, filed 15 Feb 2024.